PLAT and angioedema: In our analysis, exposure to fibrinolytics (e.g. tissue plasminogen activators (tPA)) was 16.5 fold higher in ACEi angioedema cases versus their controls. Angioedema is described to occur in 1.7 [61] -7.9% [62] of all cerebral vascular accident patients treated with tissue plasminogen activators (tPA) and is reported to occur more frequently when ACEi is taken concomitantly [61, 62, 63].